Authors:
Out, HJ
David, I
Ron-El, R
Friedler, S
Shalev, E
Geslevich, J
Dor, J
Shulman, A
Ben-Rafael, Z
Fisch, B
Dirnfeld, M
Citation: Hj. Out et al., A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles, HUM REPR, 16(6), 2001, pp. 1104-1109
Authors:
Chillik, C
Young, E
Gogorza, S
Estofan, D
Neuspiller, N
Antunes, N
Borges, E
Petracco, A
Vantman, D
Fabres, C
Montoya, JM
Madero, JI
Gutierrez-Najar, A
Bronfenmajer, S
Kovac's, A
Kroeze, S
Out, HJ
Citation: C. Chillik et al., A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitrofertilization, FERT STERIL, 76(5), 2001, pp. 950-956
Authors:
Out, HJ
Braat, DDM
Lintsen, BME
Gurgan, T
Bukulmez, O
Gokmen, O
Keles, G
Caballero, P
Gonzalez, JM
Fabregues, F
Balasch, J
Roulier, R
Citation: Hj. Out et al., Increasing the daily dose of recombinant follicle stimulating hormone (Puregon((R))) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation, HUM REPR, 15(1), 2000, pp. 29-35
Citation: Hj. Out et al., What are the clinical benefits of recombinant gonadotrophins? The development of recombinant FSH (Puregon (R)): a scientific business, HUM REPR, 14(9), 1999, pp. 2189-2190
Authors:
Out, HJ
Lindenberg, S
Mikkelsen, AL
Eldar-Geva, T
Healy, DL
Leader, A
Rodriguez-Escudero, FJ
Garcia-Velasco, JA
Pellicer, A
Citation: Hj. Out et al., A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon (R)) in women undergoing ovarian stimulation, HUM REPR, 14(3), 1999, pp. 622-627